Journal
CANCER SCIENCE
Volume 102, Issue 8, Pages 1602-1604Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1349-7006.2011.01970.x
Keywords
-
Categories
Funding
- Grants-in-Aid for Scientific Research [22680063] Funding Source: KAKEN
Ask authors/readers for more resources
The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) is a recently identified fusion-type oncoprotein that exists in approximately 5% of non-small cell lung cancer (NSCLC). It has been demonstrated that NSCLC driven by EML4-ALK is strongly addicted to this fusion-type oncokinase. A clinical trial of crizotinib (PF-02341066) sponsored by Pfizer has proven this oncogene addiction in humans by demonstrating a high response rate to inhibition of ALK kinase activity. In the present study, we report on three cases harboring EML4-ALK rearrangement who were enrolled in the trial (A8081001, NCT00585195). All three patients showed favorable responses to the ALK-specific tyrosine kinase inhibitor. (Cancer Sci 2011; 102: 1602-1604)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available